Description: Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology. The company was founded in 1984 and is headquartered in Hyderabad, India.
Home Page: www.drreddys.com
8-2-337, Road No. 3
Hyderabad,
500034
India
Phone:
91 40 4900 2900
Officers
| Name | Title |
|---|---|
| Mr. Gunupati Venkateswara Prasad B.E. | Co-Chairman, MD & Member of Management Council |
| Mr. Kallam Satish Reddy | Chairman & Member of the Management Council |
| Mr. Erez Israeli M.B.A. | CEO & Member of the Management Council |
| Mr. Saumen Chakraborty B.Sc., M.B.A., B.Sc. (H), MBA-IIM | Pres, CFO & Member of Management Council |
| Mr. Deepak Sapra M.B.A. | Sr. VP, Global Head PSAI Bus. & Member of Management Council |
| Mr. M. V. Ramana M.B.A., MBA | CEO of Branded Markets - India & Emerging Countries and Member of Management Council |
| Mr. Ganadhish Kamat | Exec. VP, Global Head of Quality & Member of Management Council |
| Dr. Anil Namboodiripad | Sr. VP, Head of Proprietary Products, Head of Promius Pharma & Member of Management Council |
| Ms. Archana Bhaskar B.Sc., M.B.A. | EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council |
| Mr. Sauri Gudlavalleti B.Tech. | Sr. VP, Global Head of Integrated Product Devel. Organization & Member of Management Council |
Exchange: BSE
Country: IN : India
Currency: Indian Rupee (INR)
| Forward PE: | 20.5339 |
|---|---|
| Trailing PE: | 38.0366 |
| Price-to-Book MRQ: | 3.6256 |
| Price-to-Sales TTM: | 3.3632 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 21650 |